MedTech Acquisition Corp. (NASDAQ:MTAC) announced in an 8-K this morning that it has added a $17.8 million convertible share investment and $2 million backstop to its pending combination with TriSalus Life Sciences.
Investors are to purchase 1,785,502 series A convertible preferred shares at $10 per share. These will provide an 8% per annum dividend, which will be payable by the combined company in a mix of cash or shares to its discretion.
All of these preferred shares will be automatically converted into common shares on the four-year anniversary of the deal’s close at a price pegged to the 10-day VWAP of the combined company’s stock.
The SPAC’s sponsor has also committed that it will together with affiliates backstop at least $2 million and up to $3 million worth of shares depending upon the extent to which they participate in the convertible share investment.
The move comes as MedTech is coming up on a June 12 special meeting to extend its transaction deadline from June 22 to September 22. The sponsor has agreed to contribute $0.04 per share monthly to its trust in connection with the move. MedTech and TriSalus also agreed last month to drop the deal’s minimum cash condition to $35 million from $60 million.
MedTech initially announced its $234 million combination with TriSalus Life Sciences in November. Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device.
In April, TriSalus presented clinical data from its Phase I trials, which indicated positive results in reducing tumor growth in liver cancer patients.
Terms Tracker for the Week Ending March 14, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Once again, market volatility was the headline news this week, and while that doesn’t directly affect SPACs, it has some effect. For investors, it’s usually...
At the SPAC of Dawn The first wave of proposed SEC rules changes under the Trump administration touch upon SPACs in some unexpected ways and could portend at least a few years of peace between sponsors and their chief regulator. Earlier this month, the SEC announced that its Division of Corporation Finance would expand the...
At the SPAC of Dawn Following Wednesday’s positive CPI readings, the market is set to ingest both new jobless claims and Core PPI inflation numbers at 8:30 am ET. It might take a particularly rosy result to offset the many factors of market volatility recent. One new one got added to the bingo card this...
One of the eternal questions surrounding SPACs has been their ability or inability to match the opportunity and the performance of the traditional IPO route, and it has become received wisdom on Wall Street that SPACs don’t match up. This is ostensibly born out in in the aggregate statistics that are frequently cited. But, downside...
At the SPAC of Dawn Despite the specter of recession looming, many of the hot technology sectors that SPACs favored during the boom times appear to be coming back on the menu. Ares II (NYSE:AACT) is reportedly angling to lock down a deal with an autonomous trucking firm. Northern Genesis II and Reinvent Y each...